reservations

Looking for 2024-2025 formula COVID-19 vaccines by BioNTech and Pfizer?

To order, visit Pfizer Prime or call 1-800-533-4535. If preferred, orders may be placed with your facility’s wholesaler.

Working With Pfizer
and Pfizer Prime

tick-icon

Certainty of timing

Pfizer Prime helps eligible HCPs to ensure certainty of delivery timing and quantity†

  • 35% of doses ship within 3 weeks of US FDA regulatory action
  • The next 40% of doses ship within
    6 weeks of US FDA regulatory action
  • The final 25% of doses ship within
    8 weeks of US FDA regulatory action

†Product availability subject to US FDA regulatory action.

box-vector

Defined shipping

Helps to address storage planning issues and prepare for this upcoming fall’s vaccination campaign

  • Reserved doses are anticipated to begin shipping before in-season orders
  • Subject to regulatory action,‡ a reservation becomes an order, and then notifications and tracking will be sent to help the customer understand when orders are preparing to ship and do ship

‡Product availability subject to US FDA regulatory action.

percentage-vector

Discount available

2% early reservation discount off net price§

  • Applicable to reservations placed with Pfizer Prime for 2025-2026 formula COVID-19 vaccines by June 30, 2025 (see Pfizer Prime for additional details)

§Early reservation discount applies to reserved 2025-2026 formula COVID-19 vaccine products (following FDA approval/
authorization, commercial availability, and billing/shipment), as well as to 2025-2026 formula COVID-19 vaccine products ordered directly and shipped from Pfizer after shipment of customer’s reserved COVID-19 vaccine product(s).

Note: If preferred, you may reach out to your facility’s wholesaler. 

Reservations are available

Reservations for 2025-2026 formula COVID-19 vaccines∥ by BioNTech and Pfizer are now available for eligible HCPs.

Reservations Available

∥Product availability subject to US FDA regulatory action.

Frequently asked questions

Commonly Asked Questions About Ordering Through Pfizer Prime

What is the Pfizer Prime reservation process?

Pfizer Prime provides registered eligible HCPs an option to reserve 2025-2026 formula COVID-19 vaccines by BioNTech and Pfizer directly from Pfizer. Please log in to www.primevaccines.pfizer.com to start the reservation or account creation process.

Who can reserve 2025-2026 formula COVID-19 vaccines by BioNTech and Pfizer through Pfizer Prime?

Eligible HCPs can reserve directly from Pfizer. Eligible HCPs and others may also work with their preferred wholesalers to understand options for reserving 2025-2026 formula COVID-19 vaccines by BioNTech and Pfizer.

Note: If preferred, you may reach out to your facility's wholesaler.

Product availability subject to US FDA regulatory action.

FDA=Food and Drug Administration.

IMPORTANT SAFETY INFORMATION

Do not administer COMIRNATY® (COVID-19 Vaccine, mRNA) to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of COMIRNATY or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine.

Management of Acute Allergic Reactions

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of COMIRNATY.

Myocarditis and Pericarditis

Postmarketing data with authorized or approved mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. For COMIRNATY, the observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae.

The Centers for Disease Control and Prevention (CDC) has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).

Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY. Procedures should be in place to avoid injury from fainting.

Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to COMIRNATY.

Limitation of Vaccine Effectiveness

COMIRNATY may not protect all vaccine recipients.

Adverse Reactions

The most commonly reported adverse reactions (≥10%) after a dose of COMIRNATY were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), joint pain (up to 27.5%), fever (up to 24.3%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%).

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or https://www.pfizersafetyreporting.com or VAERS at 1-800-822-7967 or http://vaers.hhs.gov

Please click for COMIRNATY Full Prescribing Information and Patient Information.

INDICATION

COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.

Expand